Impact of Stain Normalization on Pathologist Assessment of Prostate Cancer: A Comparative Study
- PMID: 36900293
- PMCID: PMC10000688
- DOI: 10.3390/cancers15051503
Impact of Stain Normalization on Pathologist Assessment of Prostate Cancer: A Comparative Study
Abstract
In clinical routine, the quality of whole-slide images plays a key role in the pathologist's diagnosis, and suboptimal staining may be a limiting factor. The stain normalization process helps to solve this problem through the standardization of color appearance of a source image with respect to a target image with optimal chromatic features. The analysis is focused on the evaluation of the following parameters assessed by two experts on original and normalized slides: (i) perceived color quality, (ii) diagnosis for the patient, (iii) diagnostic confidence and (iv) time required for diagnosis. Results show a statistically significant increase in color quality in the normalized images for both experts (p < 0.0001). Regarding prostate cancer assessment, the average times for diagnosis are significantly lower for normalized images than original ones (first expert: 69.9 s vs. 77.9 s with p < 0.0001; second expert: 37.4 s vs. 52.7 s with p < 0.0001), and at the same time, a statistically significant increase in diagnostic confidence is proven. The improvement of poor-quality images and greater clarity of diagnostically important details in normalized slides demonstrate the potential of stain normalization in the routine practice of prostate cancer assessment.
Keywords: Gleason score; color quality; digital pathology; prostate cancer; stain normalization.
Conflict of interest statement
M. Salvi, O. Pennisi and F. Molinari are equity holders in AEQUIP S.r.l., Turin, Italy. The remaining authors declare no conflict of interest regarding the publication of this article.
Figures
References
-
- Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. Lyon. Fr. Int. Agency Res. Cancer. 2018;3:2019.
-
- WHO . Urinary and Male Genital Tumours. 5th ed. Volume 8. World Health Organization; Geneva, Switzerland: 2022. Classification of Tumours Editorial Board.
-
- Epstein J.I., Egevad L., Amin M.B., Delahunt B., Srigley J.R., Humphrey P.A. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am. J. Surg. Pathol. 2016;40:244–252. doi: 10.1097/PAS.0000000000000530. - DOI - PubMed
-
- Gleason D.F. Classification of Prostatic Carcinomas. Cancer Chemother. Rep. 1966;50:125–128. - PubMed
-
- Kirmiz S., Qi J., Babitz S.K., Linsell S., Denton B., Singh K., Auffenberg G., Montie J.E., Lane B.R. Grade Groups Provide Improved Predictions of Pathological and Early Oncologic Outcomes Compared with Gleason Score Risk Groups. J. Urol. 2019;201:278–283. doi: 10.1016/j.juro.2018.08.081. - DOI - PubMed
LinkOut - more resources
Full Text Sources
